Related Experiment Video
Updated: Jun 27, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive
Duojie Zhang1, Haimin Weng1, Zhangji Zhu1
1The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Objective:
This study aimed to evaluate the relative efficacy and safety of first-line treatment options for metastatic castration-resistant prostate cancer (mCRPC).
Methods:
We systematically searched electronic databases, including PubMed and Web of Science, for studies published from their inception to April 3rd, 2023. Inclusion criteria were: 1) Completed Phase III or IV randomized controlled trials (RCTs) registered on ClinicalTrials.gov; 2) Patients with a confirmed diagnosis of mCRPC who had not previously received chemotherapy or novel endocrine therapies. We conducted a network meta-analysis using R software (version 3.4.0). Network graphs and risk of bias graphs were generated using Stata 14.0 and RevMan 5.4, respectively. The primary outcome was overall survival (OS), and the secondary outcome was the incidence of severe adverse events (SAEs).
Results:
Seven RCTs encompassing 6,641 patients were included. The network meta-analysis revealed that both docetaxel+prednisone (DP) and cabazitaxel+prednisone (CP) significantly improved OS compared to abiraterone. Compared to placebo, DP showed comparable results to both cabazitaxel 20 mg/m^2+prednisone (C20P) and cabazitaxel 25 mg/m^2+prednisone (C25P) in terms of OS. For SAEs, both DP and C20P were superior to C25P, with no statistical difference between C20P and DP. The probability ranking plots indicated that C25P ranked highest for OS, while DP ranked highest for SAEs.
Conclusions:
Based on our network meta-analysis, we recommend cabazitaxel 20 mg/m^2+prednisone (C20P) as the primary choice for first-line management of mCRPC, followed by DP. Enzalutamide and abiraterone are suggested as subsequent options. Radium-223 may be considered for patients presenting with bone metastases.
Systematic Review Registration:
https://www.crd.york.ac.uk/prospero/, identifier CRD42023443943.
Insights
Cabazitaxel 20 mg/m² + prednisone (C20P) is recommended for first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), showing improved overall survival (OS) and fewer severe adverse events (SAEs). Docetaxel + prednisone (DP) is a viable alternative, particularly for managing SAEs.
Area of Science:
- Oncology
- Clinical Pharmacology
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) requires effective first-line treatments to improve patient outcomes.
- Evaluating the comparative efficacy and safety of novel therapies is crucial for optimizing mCRPC management.
Approach:
- A systematic literature search identified Phase III/IV randomized controlled trials (RCTs) for first-line mCRPC treatment.
- Network meta-analysis was performed to compare overall survival (OS) and severe adverse events (SAEs) of different treatment regimens.
- Statistical software R, Stata, and RevMan were utilized for data analysis and visualization.
Key Points:
- Cabazitaxel 20 mg/m² + prednisone (C20P) and docetaxel + prednisone (DP) demonstrated superior overall survival (OS) compared to abiraterone.
- DP showed comparable OS to cabazitaxel 20 mg/m² (C20P) and 25 mg/m² (C25P) versus placebo.
- DP and C20P had fewer severe adverse events (SAEs) than C25P, with no significant difference between DP and C20P.
Conclusions:
- Cabazitaxel 20 mg/m² + prednisone (C20P) is recommended as the preferred first-line therapy for mCRPC.
- Docetaxel + prednisone (DP) is a suitable alternative, especially considering its safety profile.
- Enzalutamide and abiraterone may be considered for subsequent treatment lines, with Radium-223 an option for bone metastases.
More Related Videos
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Related Concept Videos
01:21Cancer Survival Analysis
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...